DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundation

Radiotherapy

Essential points for quick revision.

Synopsis

Explain curative and palliative radiotherapy, connect target definition and fractionation to tumour control and normal-tissue risk, and recognise urgent, acute and late radiation toxicity.

  • Radiotherapy deposits ionising energy that damages DNA directly and through free radicals; fractionation allows normal-tissue repair while repeated exposure accumulates tumour effect.
  • Treatment may be definitive, neoadjuvant, adjuvant, consolidative or palliative and can use external beam, stereotactic techniques or brachytherapy.
  • CT simulation, immobilisation, target and organ-at-risk contouring, dose planning and independent checks precede the first fraction.

Key red flags

Radiation emergency context

Cord compression, airway compromise or cerebral oedema requires urgent multidisciplinary rescue; radiotherapy planning must not delay immediate stabilisation.

Investigation priorities

01
Planning CT with immobilisationFirst step

Create the reproducible geometry used for target and organ contouring.

Management branches

PlanDefine intent and geometry

Radiotherapy is proposed after diagnosis and staging.

  1. Agree curative or palliative intent, alternatives and the evidence-based dose-fractionation option at MDT and consultation.
  2. Complete simulation, immobilisation and image fusion, then contour targets and organs at risk using tumour-specific standards.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom